Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4749751 | 0.98 | FSCN1 (0.41) | FSCN1CYP3A4CYP2C19PREPHPGD | |
| SCHEMBL4749338 | 0.94 | KMT2A (0.43) | FSCN1CYP3A4CYP2C19KMT2ASMN1; SMN2 | |
| SCHEMBL4747159 | 0.94 | CYP3A4 (0.46) | FSCN1CYP3A4CYP2C19KMT2ASMN1; SMN2 | |
| SCHEMBL4746117 | 0.89 | FSCN1 (0.42) | FSCN1CYP3A4CYP2C19PIK3CAP2RX7 | |
| SCHEMBL4745430 | 0.88 | FSCN1 (0.45) | FSCN1PIK3CA | |
| SCHEMBL4743539 | 0.88 | FSCN1 (0.43) | FSCN1SMN1; SMN2P2RX7 | |
| SCHEMBL4746524 | 0.88 | FSCN1 (0.41) | FSCN1CYP3A4CYP2C19PIK3CAALDH1A1 | |
| SCHEMBL4746426 | 0.85 | FSCN1 (0.39) | FSCN1P2RX7 | |
| SCHEMBL4746320 | 0.85 | FSCN1 (0.40) | FSCN1PIK3CAP2RX7 | |
| SCHEMBL4750280 | 0.85 | FSCN1 (0.39) | FSCN1CYP3A4CYP2C19PIK3CAP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677599-A4 | HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2008-10-22 | — | — | EP | claimed |
| US-7435735-B2 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-10-14 | — | — | US | claimed |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | claimed |
| EP-1677599-A1 | HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2005041664-A1 | HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-7435735-B2 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435735-B2 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435735-B2 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | DHPS, DPYD, TYMP | FSCN1 4879/4885CYP3A4 496/4885CYP2C19 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.